Axsome Therapeutics Quarterly Cash Flow Statement
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Axsome Therapeutics generated -$33.0 million of operating cash flow and spent $450,000 on capital expenditures. That left free cash flow of -$33.4 million, a free-cash-flow margin of -15.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -51.31M | -64.54M | -28.56M | -47.23M | -47.97M | -59.41M | -74.91M | -64.60M | -79.34M | -68.36M | -98.65M | -62.20M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 143.00K | 116.00K | 114.00K | 120.00K | 120.00K | 149.00K | 129.00K | 131.00K | 140.00K | 132.00K | 133.00K | 136.00K |
| Stock-Based Compensation | 27.15M | 23.44M | 22.73M | 23.10M | 24.61M | 23.31M | 21.99M | 21.66M | 21.38M | 20.19M | 18.91M | 14.84M |
| Change in Working Capital | -60.02M | 11.46M | -20.29M | -40.08M | -33.24M | -5.98M | -11.29M | 447.00K | -10.67M | 6.39M | -9.71M | -23.20M |
| Operating Cash Flow | -32.95M | -20.70M | -18.65M | 1.05M | -32.42M | -43.38M | -26.20M | -18.63M | -30.11M | -53.47M | -30.36M | -53.55M |
| Capital Expenditures | -450.00K | -121.00K | -71.00K | -58.00K | -13.00K | -338.00K | -30.00K | -90.00K | -52.00K | -98.00K | -7.00K | -371.00K |
| Investing Cash Flow | -450.00K | -121.00K | -71.00K | -58.00K | -13.00K | -338.00K | -30.00K | -90.00K | -52.00K | -98.00K | -7.00K | -371.00K |
| Debt Repaid | -70.00M | -70.00M | -70.00M | -70.00M | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 48.15M | 2.99M | 16.39M | 21.27M | 34.54M | 29.27M | 14.24M | 30.41M | 14.38M | -1.19M | -2.00K | 33.37M |
| Net Change in Cash | 14.74M | -17.83M | -2.34M | 22.26M | 2.11M | -14.44M | -11.99M | 11.68M | -15.78M | -54.75M | -30.37M | -20.55M |
| Free Cash Flow | -33.40M | -20.82M | -18.72M | 988.00K | -32.44M | -43.71M | -26.23M | -18.72M | -30.16M | -53.56M | -30.37M | -53.92M |
This table shows 12 quarterly periods of Axsome Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a cash flow statement?